KUALA LUMPUR (Oct 14): A report that Malaysia will be a priority recipient of China's COVID-19 vaccine bodes well for the pharmaceutical counters and companies which had secured the vaccine deals.
At 10.19 am, Pharmaniaga rose 10 sen to RM5.22, Apex Healthcare went up three sen to RM3.43, Bintai Kinden perked one sen to 68.5 sen, while Duopharma and Kotra Industries advanced four sen each to RM3.64 and RM3.23, respectively.
Ho Wah Genting, of which its wholly-owned subsidiary, HWGB Biotech Sdn Bhd entered into a Memorandum of Understanding (MoU) with Xinkexian (Beijing) Biotechnology Co, Ltd (XKX) last month to consider appointing XKX as its non-exclusive manufacturer to produce COVID-19 vaccines, also improved 10 sen to 74 sen.
In a joint news conference after the bilateral meeting with Chinese Foreign Minister Wang Yi here, yesterday, Foreign Minister Datuk Seri Hishammuddin Tun Hussein said China had agreed to list Malaysia as a priority recipient of the China-produced COVID-19 vaccine once it successfully developed.
He said China had announced the vaccine is now being developed in the country and could be ready for use by the general public as early as November.
Meanwhile, Wang Yi said Malaysia is a good friend of China, and the country enjoys traditional friendship.
“If there is any need of Malaysia for vaccine, we are open for that and we stand ready to pursue details of cooperation and to carry out collaboration on that,” he said.